FIPO23 Phase I/II, multi center, Open Label, First-in-human, Dose Escalation and Expansion study to investigate the Safety, Pharmacokinetics, and anti-tumors efficacy of the glyco-humanized polyclonal antibody XON7 in patients with advanced or metastatic solid tumors.
Phase 1
Recruiting
- Conditions
- Advanced or metastatic solid tumorsTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-505266-29-00
- Lead Sponsor
- Xenothera
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 246
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method